SURVYR

SEPN

Septerna, Inc.
$44.14
+$2.76 (6.67%)Oct 27 close
Healthcare CompareTechnicals
Model valuationLooks undervaluedDCF base $173
1M3M6M1Y2Y
-22%+15%+52%+89%+126%Oct 2025Oct 2026Apr 202652w high $51.1052w low $17.55
SEPNSPY
Wall St. Highest PT $62.00 (+40.5%) Wall St. Avg PT $54.22 (+22.8%)
$18$30$41$52$64POC $26Hi $62Avg $54
Underwater Drawdown %Max DD -26.0%Current -8.4%
0.0%-26.0%
Relative Strength vs SPY+81.6% vs SPYOutperforming
+114%0%-114%
1W
+$4.79 (12.17%)
1M
+$6.37 (16.87%)
3M
+$10.17 (29.94%)
6M
+$19.85 (81.72%)
YTD
+$16.26 (58.32%)
1Y
+$21.52 (95.14%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
10 analysts · mean score 1.90
1 = Strong Buy · 5 = Sell
Strong Buy110%
Buy990%
Hold00%
Underperform00%
Sell00%
Wall Street consensus · as of Oct 23, 2026
Analyst price targets · 9 analysts
Current price$44.14
Average target$54.22
+$10.08 (+22.8%) upsideaverage target vs current price
CurrentAverageMedian
Low$48.00
Median$51.00
High$62.00
12-month Wall Street target range · as of Oct 23, 2026
Recent analyst rating changes · 30
Reiterated
2026-08-19 · JP Morgan reiterated Overweight on SEPN
Reiterated
2026-08-13 · Jones Trading reiterated Buy on SEPN
Reiterated
2026-08-12 · Wells Fargo reiterated Overweight on SEPN
Reiterated
2026-08-12 · HC Wainwright & Co. reiterated Buy on SEPN
Reiterated
2026-08-11 · Guggenheim reiterated Buy on SEPN
Reiterated
2026-07-01 · Guggenheim reiterated Buy on SEPN
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Health check

Financial health
DistressGrey zoneSafe
Safe zone
Altman Z-score 6.4
Above 2.99 is the safe zone, below 1.81 the distress zone.
Quality
WeakAverageStrong
Average
Piotroski F-score 5 of 9
See the tests
  • ✗Positive net income
  • ✓Positive operating cash flow
  • ✓Return on assets improved
  • ✓Cash flow above net income
  • ✓Long-term debt / assets fell
  • ✗Current ratio improved
  • ✗No share dilution
  • ✗Gross margin improved
  • ✓Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$1.9B
P/E (next 12 months, estimated)-20.8
52-week range$17.55 – $51.10
Revenue growth (latest quarter vs a year ago)+22375.6%
Dividend yieldNo dividend
Average analyst price target$54.22 (+23%)

What they do

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Looks undervalued
Model read-out from the numbers below, not advice. Score +3 (DCF counts double).
▲DCF (base case)above the price by 291%
•Piotroski F-score5/9
▲Altman Z6.4 (safe)
▲Analyst target+23% (9 analysts)

Discounted cash flow

Bear
$80
+82%
growth 18% · disc. 10.2% · term. 2.0%
Base
$173
+291%
growth 30% · disc. 9.2% · term. 2.5%
Bull
$322
+629%
growth 38% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Today's price assumes free cash flow grows about 2% a year for 10 years.
Implied
+2%/yr
FCF, last 3 yrs
n/a
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
n/a
Revenue, last 5 yrs
n/a
Same inputs as the DCF above: trailing free cash flow 0.1B, 9.2% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $-1.94 vs trailing $-0.54. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
–
Operating margin
-44.0%
FCF margin
106.3%
Net margin
-24.5%
Return on equity
-6.3%
Return on invested capital
-238.9%
Net debt / EBITDA
–
Current ratio
5.0×
Interest cover
–
Cash conversion (OCF/NI)
–
Piotroski F-score 5/9 · last two fiscal years
✗ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 6.4 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$54
+23%
Analysts
9
None
Range
$48–$62
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$46.0M$-48.9M$109.7M
2024$1.1M$-71.8M$-69.6M
2023$151.0K$4.2M$-41.6M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

For information only · Important disclosures

Grades vs sector

No sector grades for SEPN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Held by 1 of 7 live models: New Highs Growth.

New Highs Growth
4.0% of the book
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book
Why it's in the New Highs Growth

Qualified on Pharma, -19% from 52-week high, revenue +22376% y/y, 12-1 momentum +110%.

What would knock it out: Drops out if it falls outside the top 25 at the next rebalance (Oct 30). In the latest preview (2026-10-27) it ranks 15th.

Earnings & events

SEPN earningsNext report in 13 days
Next report · quarter Sep 2026
Mon Nov 9, 2026Time not confirmed
EPS consensus-$0.40 range -$0.69–-$0.24
Revenue consensus$20.8M 10 analysts
Last 4 quarters · EPS vs estimate
Aug 10, 2026-$0.29est -$0.49+41.2%Above estimates
May 11, 2026-$0.19est -$0.44+56.9%Above estimates
Mar 9, 2026-$0.24est -$0.22−8.5%Below estimates
Nov 10, 2025-$0.10est $0.79−112.3%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-25 13:18:14 ET
24-1125-0325-0525-0825-1126-0326-0526-08-8.400.93
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$26.7M+22375.6%
2026-03-31$26.5M–
2025-12-31$24.1M–
2025-09-30$21.5M–
2025-06-30$119.0K–

News & catalysts

More news
Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?
Simply Wall St. · Sep 14
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 10
Septerna to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 01
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
GlobeNewswire · Aug 25
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
Zacks · Aug 10

Research

New Highs Growth: rebalance of Sep 30, 2026Oct 22, 2026
Rating changes
Reiterated
2026-08-19 · JP Morgan reiterated Overweight on SEPN
Reiterated
2026-08-13 · Jones Trading reiterated Buy on SEPN
Reiterated
2026-08-12 · Wells Fargo reiterated Overweight on SEPN
Reiterated
2026-08-12 · HC Wainwright & Co. reiterated Buy on SEPN
Reiterated
2026-08-11 · Guggenheim reiterated Buy on SEPN
Reiterated
2026-07-01 · Guggenheim reiterated Buy on SEPN

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Bhatt Elizabeth
President and COO · 2026-10-15
Sell
$109.3K
Bhatt Elizabeth
President and COO · 2026-10-15
Sell
$40.3K
Long Daniel D.
SVP, Drug Discovery · 2026-09-01
Sell
$126.1K
Ra Capital Management, L.P.
Director, 10% owner · 2026-08-12
Sell
$31.7M
Ra Capital Management, L.P.
Director, 10% owner · 2026-08-12
Sell
$31.7M
Third Rock Ventures V, L.P.
10% owner · 2026-08-12
Sell
$7.2K
Third Rock Ventures V, L.P.
10% owner · 2026-08-12
Sell
$7.4M
Bhatt Elizabeth
President and COO · 2026-08-11
Sell
$1.1M
Long Daniel D.
SVP, Drug Discovery · 2026-08-03
Sell
$80.9K
Long Daniel D.
SVP, Drug Discovery · 2026-08-03
Sell
$34.0K
None
None · None
Sell
–

Stats refreshed 2026-10-25 13:18:14 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026